{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:23937",
      "entity_text" : "OS",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ02052",
      "entity_text" : "bevacizumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "In second-line treatment for mCRC, the ECOG E3200 trial showed that addition of bevacizumab to FOLFOX4 regimen increased RR, PFS, and OS [XREF_BIBR].",
  "reading_complete" : "2020-08-08T12:39:18Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T12:34:09Z",
  "trigger" : "increased",
  "evidence" : [ "bevacizumab to FOLFOX4 regimen increased RR, PFS, and OS" ],
  "pmc_id" : "4130202",
  "score" : 0
}